Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC-Reference-Cited by-同舟云学术

Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC

Published:2018-06 Issue:6 Volume:13 Page:821-830
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Buder Anna,Hochmair Maximilian J.,Schwab Sophia,Bundalo Tatjana,Schenk Peter,Errhalt Peter,Mikes Romana E.,Absenger Gudrun,Patocka Kurt,Baumgartner Bernhard,Setinek Ulrike,Burghuber Otto C.,Prosch Helmut,Pirker Robert,Filipits Martin

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

2. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

3. Gefitinib versus cisplatin plus docetaxel in patients with non–small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non–small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non–small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoplasmonic Detection of EGFR Mutations Based on Extracellular Vesicle-Derived EGFR–Drug Interaction;ACS Applied Materials & Interfaces;2024-02-09

2. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC;Scientific Reports;2024-01-03

3. Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib;Scientific Reports;2023-11-27

4. Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy;Cancers;2023-07-07

5. Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications;International Journal of Molecular Sciences;2023-06-28